On Tuesday, Nutex Health got an upgrade for its IBD SmartSelect Composite Rating from 93 to 97.
Discover The 3 Keys To Successful Stock Investing
The new score indicates the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria. Winning stocks often have a 95 or higher grade in the early stages of a new price run, so that's a good item to have on your checklist when looking for the best stocks to buy and watch.
Nutex Health is currently extended beyond a proper buy zone after clearing the 69.45 buy point in a consolidation.
One weak spot is the company's 41 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
The company posted a 0% increase in earnings for Q4. Top line growth increased 270%, up from 26% in the prior report. That marks one quarter of accelerating revenue gains. The company's next quarterly report is expected on or around May. 19.
Nutex Health earns the No. 1 rank among its peers in the Medical-Hospitals industry group. Tenet Healthcare and Universal Health Cl B are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
